Teva Pharmaceutical Industries has formed a collaboration with Intel Corporation to develop a wearable device and machine-learning platform for use in Huntington disease (HD). This platform will continuously monitor and analyze key symptoms that impact daily living, in an effort to better understand disease progression and improve treatment evaluation. This collaboration will leverage Intel’s capabilities in analytics and algorithm developmentfor movement detection with Teva’s knowledge and experience in HD treatment and research.

Teva, working in collaboration with Intel, will deploy this technology platform within an ongoing Phase II study. As part of this technology platform, patients will be asked to use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure their general functioning and movement. These data will be wirelessly streamed to a cloud-based platform specifically developed by Intel to analyze data from wearable devices. The study will start toward the end of 2016 and will take place in centers in the US and Canada.

This cloud-based solution for analyzing wearable device data is being developed using the open-source Intel Trusted Analytics Platform (TAP), a software platform optimized for performance and security to accelerate the creation of advanced analytics and machine learning solutions. Initial development was done in collaboration with The Michael J. Fox Foundation for use in Parkinson’s disease research.

Source: Teva Pharmaceutical Industries